PT-141
Also known as: Bremelanotide · Vyleesi
An FDA-approved melanocortin receptor agonist that treats sexual dysfunction by acting on the central nervous system rather than the vascular system.
Overview
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was originally developed from the tanning peptide Melanotan II. During clinical trials of Melanotan II, researchers noticed a significant and unexpected side effect — increased sexual arousal and desire. This led to the development of PT-141 as a targeted sexual dysfunction treatment. Unlike PDE5 inhibitors (Viagra, Cialis) that work by increasing blood flow to the genitals, PT-141 works through the central nervous system by activating melanocortin-4 receptors (MC4R) in the hypothalamus.
This means it addresses the desire and arousal components of sexual function, not just the mechanical aspects. PT-141 is FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only FDA-approved on-demand treatment for low sexual desire. In men, it has shown efficacy for erectile dysfunction, including in cases that do not respond to PDE5 inhibitors, because it works through a completely different mechanism. The peptide is typically administered 45 minutes before anticipated sexual activity.
Mechanism of Action
Agonist of melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the hypothalamus. Activates central pathways involved in sexual arousal and desire. Modulates dopaminergic and oxytocinergic signaling in brain regions associated with sexual behavior. Does not directly affect vascular smooth muscle.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for PT-141. Always consult a healthcare professional before combining compounds.
Use Caution (1)
PT-141 (bremelanotide) is derived from Melanotan 2. Both act on melanocortin receptors. Using together may cause excessive nausea, blood pressure changes, and flushing.
Synergistic (2)
PT-141 works centrally (brain) to increase sexual desire while tadalafil works peripherally (vasculature) to support erectile function. Complementary mechanisms.
Testosterone provides the hormonal foundation for libido while PT-141 enhances central arousal signaling. Effective combination for comprehensive sexual health.
Scientific References
Quick Reference
Typical Dose
1-2 mg
Frequency
As needed, 45 minutes before activity
Route
Subcutaneous injection
Half-Life
~2.7 hours
Cycle Length
As needed; not more than once per 24 hours
FDA Status
FDA approved (Vyleesi) for HSDD in premenopausal women
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.